MétaCan
Menu
Back to cohort
Record W4207010819 · doi:10.1016/j.jtct.2022.01.017

Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research

2022· article· en· W4207010819 on OpenAlexaff
Hemant S. Murthy, Kwang Woo Ahn, Noel Estrada‐Merly, Hassan B. Alkhateeb, Susan Bal, Mohamed A. Kharfan‐Dabaja, Bhagirathbhai Dholaria, Francine M. Foss, Lohith Gowda, Deepa Jagadeesh, Craig S. Sauter, Muhammad Bilal Abid, Mahmoud Aljurf, Farrukh T. Awan, Ulrike Bacher, Sherif M. Badawy, Minoo Battiwalla, Christopher Bredeson, Jan Černý, Saurabh Chhabra, Abhinav Deol, Miguel Ángel Díaz, Nosha Farhadfar, César O. Freytes, James Gajewski, Manish J. Gandhi, Siddhartha Ganguly, Michael R. Grunwald, Joerg Halter, Shahrukh K. Hashmi, Gerhard Hildebrandt, Yoshihiro Inamoto, Antonio Jiménez, Matt Kalaycio, Rammurti T. Kamble, Maxwell M. Krem, Hillard M. Lazarus, Aleksandr Lazaryan, Joseph Maakaron, Pashna N. Munshi, Reinhold Munker, Aziz Nazha, Taiga Nishihori, Olalekan O. Oluwole, Guillermo Ortí, Dorothy C. Pan, Sagar S. Patel, Attaphol Pawarode, David A. Rizzieri, Nakhle S. Saba, Bipin N. Savani, Sachiko Seo, Celalettin Üstün, Marjolein van der Poel, Leo F. Verdonck, John L. Wagner, Baldeep Wirk, Betül Oran, Ryotaro Nakamura, Bart L. Scott, Wael Saber

Bibliographic record

VenueTransplantation and Cellular Therapy · 2022
Typearticle
Languageen
FieldMedicine
TopicChronic Lymphocytic Leukemia Research
Canadian institutionsOttawa Hospital
FundersJanssen PharmaceuticalsNational Institute of Allergy and Infectious DiseasesOffice of Naval ResearchNational Heart, Lung, and Blood InstituteU.S. Public Health ServiceHealth Resources and Services AdministrationU.S. Food and Drug AdministrationAstellas PharmaDaiichi-SankyoBayer FundKiadis PharmaTG TherapeuticsMedical College of WisconsinChimerixJazz PharmaceuticalsTakeda Pharmaceuticals U.S.A.AbbVieMerckSpectrum PharmaceuticalsNational Cancer InstituteGilead SciencesKaryopharm TherapeuticsNovartisGlaxoSmithKlineCSL BehringBristol-Myers SquibbAstraZenecaAmgenFalk FoundationCareDxAmyloidosis FoundationPfizerAlexion PharmaceuticalsAstellas Pharma US
KeywordsMedicineInternal medicineHazard ratioTransplantationProlymphocytic leukemiaRegimenCumulative incidenceGastroenterologyHematopoietic stem cell transplantationAlemtuzumabOncologyConfidence intervalLeukemiaSurgeryChronic lymphocytic leukemia

Abstract

fetched live from OpenAlex

T cell prolymphocytic leukemia (T-PLL) is a rare, aggressive malignancy with limited treatment options and poor long-term survival. Previous studies of allogeneic hematopoietic cell transplantation (alloHCT) for T-PLL are limited by small numbers, and descriptions of patient and transplantation characteristics and outcomes after alloHCT are sparse. In this study, we evaluated outcomes of alloHCT in patients with T-PLL and attempted to identify predictors of post-transplantation relapse and survival. We conducted an analysis of data using the Center for International Blood and Marrow Transplant Research database on 266 patients with T-PLL who underwent alloHCT between 2008 and 2018. The 4-year rates of overall survival (OS), disease-free survival (DFS), relapse, and treatment-related mortality (TRM) were 30.0% (95% confidence interval [CI], 23.8% to 36.5%), 25.7% (95% CI, 20% to 32%), 41.9% (95% CI, 35.5% to 48.4%), and 32.4% (95% CI, 26.4% to 38.6%), respectively. In multivariable analyses, 3 variables were associated with inferior OS: receipt of a myeloablative conditioning (MAC) regimen (hazard ratio [HR], 2.18; P < .0001), age >60 years (HR, 1.61; P = .0053), and suboptimal performance status, defined by Karnofsky Performance Status (KPS) <90 (HR, 1.53; P = .0073). Receipt of an MAC regimen also was associated with increased TRM (HR, 3.31; P < .0001), an elevated cumulative incidence of grade II-IV acute graft-versus-host disease (HR, 2.94; P = .0011), and inferior DFS (HR, 1.86; P = .0004). Conditioning intensity was not associated with relapse; however, stable disease/progression was correlated with increased risk of relapse (HR, 2.13; P = .0072). Both in vivo T cell depletion (TCD) as part of conditioning and KPS <90 were associated with worse TRM and inferior DFS. Receipt of total body irradiation had no significant effect on OS, DFS, or TRM. Our data show that reduced-intensity conditioning without in vivo TCD (ie, without antithymocyte globulin or alemtuzumab) before alloHCT was associated with long-term DFS in patients with T-PLL who were age ≤60 years or who had a KPS >90 or chemosensitive disease.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.039
GPT teacher head0.305
Teacher spread0.265 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations23
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueTransplantation and Cellular TherapySame topicChronic Lymphocytic Leukemia ResearchFrench-language works237,207